
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is well-positioned in the emerging market of AI-driven medical diagnostics, with its DeepView System offering a unique and efficient way to assess wound healing potential. With a large and under-penetrated market opportunity, as well as recent funding from BARDA to support the development and commercialization of the DeepView System, the company has a strong potential for growth. However, risks exist in terms of competition, delays in regulatory and clinical timelines, and limited reimbursement. Based on the company's current revenue guidance, the analyst estimates a strong CAGR in the coming years and assigns a Buy rating with a $4 price target on the stock.
Bears say
Spectral AI is expected to recognize revenue from its existing BARDA contract and achieve its regulatory and clinical milestones, but risks such as limited awareness of the technology, competition, and delays to timelines may impede its success. The company has reported an increase in R&D revenue and promising cash reserves but has yet to bring a commercial technology to the market.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares